For patients with T2D, primary prevention of MI and CAD with a GLP1-RA was demonstrated with dulaglutide, which reduced the relative risk of MACE by 12% after >5 years of treatment.113 Three GLP1-RAs—dulaglutide, liraglutide, and semaglutide—have demonstrated secondary prevention of MACE, with specific reductions in strokes. This evidence concerns the gene GLP1R and Stroke.